AnalystsKaveri PohlmanKaveri Pohlman's Stock Forecasts
AnalystsKaveri Pohlman
Sectors:
Industries:
Analyst Ranking
Top 28%
#1438 out of 5197 analysts
Average Return
+3.25%
Win Rate
35%13 out of 37
Risk vs Reward
Poor
Good
Kaveri Pohlman's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Ventyx Biosciences IncVTYX | +287.78% | $3.60 | $13.96 | 2025-10-01 - 2026-02-18 | Strong Buy |
Checkmate Pharmaceuticals IncCMPI | +222.67% | $3.22 | $10.39 | 2022-03-30 - 2022-04-20 | Strong Buy |
Ambrx Biopharma IncAMAM | +137.69% | $11.78 | $28.00 | 2023-09-12 - 2024-03-06 | Strong Buy |
Rapt Therapeutics IncRAPT | +123.23% | $25.79 | $57.57 | 2025-09-30 - 2026-01-20 | Strong Buy |
Macrogenics IncMGNX | +116.15% | $7.12 | $15.39 | 2023-03-21 - 2024-03-20 | Strong Buy |
Kaveri Pohlman Analyst Color
Get additional color on Kaveri Pohlman's coverage of popular stocks
Kaveri Pohlman's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Rapt Therapeutics IncRAPT | 3 | Hold | $58.00 | +0.45% | Downgrades | a month ago |
Janux Therapeutics IncJANX | 3 | Hold | $12.00 | -9.16% | Downgrades | a month ago |
Palisade Bio IncPALI | 1 | Strong Buy | $12.00 | +610.06% | Initiates Coverage On | 2 months ago |
Structure Therapeutics IncGPCR | 1 | Strong Buy | $99.00 | +44.82% | Maintains | 2 months ago |
Palvella Therapeutics IncPVLA | 1 | Strong Buy | $200.00 | +151.26% | Initiates Coverage On | 2 months ago |
Jade Biosciences IncJBIO | 1 | Strong Buy | $25.00 | +72.89% | Initiates Coverage On | 3 months ago |
Trevi Therapeutics IncTRVI | 1 | Strong Buy | $21.00 | +106.08% | Maintains | 3 months ago |
Zura Bio LtdZURA | 1 | Strong Buy | $18.00 | +189.86% | Initiates Coverage On | 3 months ago |
Sagimet Biosciences IncSGMT | 1 | Strong Buy | $29.00 | +452.38% | Initiates Coverage On | 4 months ago |
Ventyx Biosciences IncVTYX | 1 | Strong Buy | $11.00 | -21.20% | Initiates Coverage On | 5 months ago |
Oruka Therapeutics IncORKA | 1 | Strong Buy | $46.00 | +42.55% | Maintains | 5 months ago |
Arrivent Biopharma IncAVBP | 1 | Strong Buy | $32.00 | +37.63% | Initiates Coverage On | 8 months ago |
Genmab AGMAB | 3 | Strong Buy | $47.00 | N/A | Maintains | 2 years ago |
Macrogenics IncMGNX | 3 | Strong Buy | $9.00 | N/A | Maintains | 2 years ago |
Cullinan Therapeutics IncCGEM | 2 | Strong Buy | $30.00 | N/A | Maintains | 2 years ago |
Xencor IncXNCR | 1 | Strong Buy | $38.00 | N/A | Maintains | 2 years ago |
Nuvation Bio IncNUVB | 2 | Strong Buy | $5.00 | N/A | Upgrades | 2 years ago |
Pyxis Oncology IncPYXS | 1 | Strong Buy | $8.00 | N/A | Initiates Coverage On | 2 years ago |
Exelixis IncEXEL | 1 | Strong Buy | $27.00 | N/A | Initiates Coverage On | 2 years ago |
Ambrx Biopharma IncAMAM | 1 | Strong Buy | $26.00 | N/A | Initiates Coverage On | 2 years ago |
Arcus Biosciences IncRCUS | 1 | Strong Buy | $70.00 | N/A | Reiterates | 2 years ago |
Oncosec Medical IncONCSQ | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Shattuck Labs IncSTTK | 1 | Strong Buy | $12.00 | N/A | Initiates Coverage On | 3 years ago |
Cytomx Therapeutics IncCTMX | 2 | Strong Buy | $8.00 | N/A | Maintains | 4 years ago |
Neximmune IncNEXI | 1 | Strong Buy | $125.00 | N/A | Initiates Coverage On | 4 years ago |
Checkmate Pharmaceuticals IncCMPI | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Oncternal Therapeutics IncONCT | 1 | Strong Buy | $100.00 | N/A | Initiates Coverage On | 4 years ago |
Sonnet Biotherapeutics Holdings IncSONN | 2 | Strong Buy | $4,928.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.